PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00856687
- Locations
- 🇬🇧
Pfizer Investigational Site, Harrow, Middlesex, United Kingdom
Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PF 03882845 and Placebo
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00856258
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 795
- Registration Number
- NCT00856544
- Locations
- 🇻🇪
Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela
A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00855101
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 717
- Registration Number
- NCT00853385
- Locations
- 🇬🇧
Pfizer Investigational Site, Dudley, West Midlands, United Kingdom
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00853112
- Locations
- 🇩🇪
Thoraxklinik am Universitaetsklinikum, Heidelberg, Germany
🇮🇳Department Of Cardiology, Sri Venkateswara Institute Of Medical Sciences, Tirupati, Andhra Pardesh, India
🇨🇦Lawson Health Research Institute, London, Ontario, Canada
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2013-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00852397
- Locations
- 🇯🇵
Pfizer Investigational Site, Osaka, Japan
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 429
- Registration Number
- NCT00848354
- Locations
- 🇨🇴
Reumalab, Medellin, Antioquia, Colombia
🇨🇴Centro de Reumatologia y Ortopedia, Barranquilla, Atlantico, Colombia
🇨🇴Centro Integral de Reumatologia e Inmunologia LTDA, Bogota, Cundinamarca, Colombia
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 800
- Registration Number
- NCT00847613
- Locations
- 🇺🇦
Pfizer Investigational Site, Vinnitsa, Ukraine
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3538
- Registration Number
- NCT00845273